Patents by Inventor Laura Carter
Laura Carter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240095680Abstract: A method of implementing administrative services for a compensation platform is disclosed. One or more interactive compensation representation views are generated based on an evaluation of mapping rules against a flexible ontology and current data state, the flexible ontology comprising customizable compensation components, relationships, and properties. One or more compensation representation views are dynamically updated in real-time in response to changes in compensation data, user context, or access permissions without requiring manual regeneration of the one or more compensation representations. The one or more interactive compensation representation views include a user interface element displayed in response to a user selection of compensation data, wherein the user interface element provides direct access to compensation information relevant to the selected compensation data without requiring a change to another screen or another user context.Type: ApplicationFiled: September 21, 2023Publication date: March 21, 2024Inventors: Jenna Nicole Soojin Lee, Ian William Richard, Laura Elizabeth Pearson, Christian Nguyen, Tovin Thomas, Adam Carter, David Achee, David Christopher Sally, Miranda Howitt, Vincent Yao, Seth Goldenberg, Aimee Jin Peng, William Qingdong Yan, Rahul Rangnekar, Matthew Stephen Wysocki, Michael Ryan Shohoney, Tyler Kowalewski, Ami Tushar Bhatt, Jeffrey Ryan Gurr, Cap Watkins, Ryan Maas, Asha Camper Singh, Leonardo Faria, Elliot Piersa Dahl, Nina Ojeil
-
Publication number: 20240095645Abstract: A method of generating customizable goal representation is disclosed. A request from a user to view a goal representation is received. A flexible goal ontology is accessed that comprises one or more goal entities, one or more goal relationships between the goal entities, or one or more goal properties, the one or more goal properties including one or more metadata attributes relating to the one or more goal entities. A set of mapping rules is obtained that defines mappings between one or more goals. The set of mapping rules is evaluated to assemble a customized goal representation tailored to the user. The customized goal representation is updated based on a revaluation of the mapping rules affected by changes to the one or more goal entities, the one or more goal relationships, or the one or more properties.Type: ApplicationFiled: September 21, 2023Publication date: March 21, 2024Inventors: Sven Martin Andreas Elfgren, Friedrich I. Riha, Elliot Piersa Dahl, Eric Koslow, Nicole Jensen McMullin, Natasha Hede, Connie Lynn Chen, Alexa Jean Kriebel, Chije Wang'ati, JR., Megan McGowan, Ami Tushar Bhatt, Jeffrey Ryan Gurr, Tyler Kowalewski, Rahul Rangnekar, Byron Sha Yang, Jerry Wu, Ricky Rizal Zein, Romain Beauxis, Adnan Chowdhury, Priya Balasubramanian, Gilles Yvetot, Shaylan Hawthorne, Adnan Pirzada, Matthew Michael Parides, Jenna Nicole Soojin Lee, Ian William Richard, Laura Elizabeth Pearson, Christian Nguyen, Tovin Thomas, Adam Carter, David Achee, David Christopher Sally, Miranda Howitt, Vincent Yao, Seth Goldenberg, Aimee Jin Peng, William Qingdong Yan, Matthew Stephen Wysocki, Michael Ryan Shohoney, Ryan Maas, Asha Camper Singh, Leonardo Faria, Elliot Piersa Dahl
-
Publication number: 20230201346Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: December 19, 2022Publication date: June 29, 2023Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine ETTINGER, Jodi KARNELL, Melissa DAMSCHRODER, Partha CHOWDHURY, Xiaodong XIAO, Ping TSUI, Reena VARKEY, Stacey DRABIC, Laura CARTER, Ronald HERBST, Qun DU, Brian Michael NAIMAN
-
Patent number: 11529415Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: February 5, 2020Date of Patent: December 20, 2022Assignee: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20200164069Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: February 5, 2020Publication date: May 28, 2020Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 10588969Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: June 11, 2018Date of Patent: March 17, 2020Assignee: Boston Pharmaceuticals, Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20180318416Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: June 11, 2018Publication date: November 8, 2018Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 10022443Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: April 7, 2015Date of Patent: July 17, 2018Assignee: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20170173149Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: April 7, 2015Publication date: June 22, 2017Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20170159089Abstract: The present invention relates to a method of producing glucose from a cellulosic biomass using enzymatic hydrolysis. The present invention also relates to a device for performing such method.Type: ApplicationFiled: December 4, 2016Publication date: June 8, 2017Applicant: Arbiom Inc.Inventors: Lisette Tenlep, Pavani Mandali, Pratik Darvekar, Laura Carter, Cassidy Strange, Rebekah Kendall, Samuel Smith
-
Patent number: 8247227Abstract: A method of generating a population of dendritic cell (DC) precursors includes obtaining a population of progenitor cells from a subject and culturing the progenitor cells in a culture medium. The culture medium can include Flt3 ligand and interleukin-6 and be free of granulocyte-macrophage colony-stimulating factor.Type: GrantFiled: August 28, 2007Date of Patent: August 21, 2012Assignees: The Cleveland Clinic Foundation, Trustees of the University of Pennsylvania, National Institutes of HealthInventors: Peter A. Cohen, Suyu Shu, Gary K. Koski, Charles S. Carter, Laura Carter, legal representative, Brian J. Czerniecki
-
Patent number: 7198789Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.Type: GrantFiled: October 4, 2002Date of Patent: April 3, 2007Assignee: Genetics Institute, LLCInventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger
-
Patent number: 7189400Abstract: Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein.Type: GrantFiled: October 4, 2001Date of Patent: March 13, 2007Assignee: Genetics Institute, LLCInventors: Laura Carter, Matthew J. Whitters, Mary Collins, Deborah A. Young, Debra D. Donaldson, Lesile D. Lowe, Michelle Unger
-
Publication number: 20060210567Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: December 22, 2003Publication date: September 21, 2006Inventors: Mary Collins, Clive Wood, Beatriz Carreno, Deborah Luxenberg, Jason Jussif, Laura Carter, Frances Bennett, Viia-Valge Archer, Caroline Russell
-
Publication number: 20030108549Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.Type: ApplicationFiled: October 4, 2002Publication date: June 12, 2003Applicant: WyethInventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger
-
Publication number: 20030049798Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.Type: ApplicationFiled: October 4, 2001Publication date: March 13, 2003Inventors: Laura Carter, Matthew J. Whitters, Mary Collins, Deborah A. Young, Debra D. Donaldson, Leslie D. Lowe, Michelle Unger